2L
NKTR icon

22NW LP’s Nektar Therapeutics NKTR Stock Holding History

22NW LP’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.2M Sell
281,115
-50,000
-15% -$2.85M 13.86% 2
2025
Q4 		$14M Hold
331,115
– – 5.89% 4
2025
Q3 		$18.8M Buy
331,115
+185,000
+127% +$6.12M 8.88% 4
2025
Q2 		$3.78M Sell
146,115
-2
-0% -$22 2.38% 12
2025
Q1 		$1.49M Hold
146,117
– – 1% 17
2024
Q4 		$2.04M Buy
+146,117
New +$2.58M 1.29% 13

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

22NW LP's NKTR Position: Q1 2026 in Review

22NW LP reduced its Nektar Therapeutics (NKTR) stake by 15% in Q1 2026, selling an estimated $2.85M and leaving 281,115 shares worth $20.2M. The position accounts for 13.86% of the portfolio, ranked #2.

22NW LP first reported a position in NKTR in Q4 2024 and has held it in 6 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • 22NW LP held 281,115 shares of Nektar Therapeutics worth $20.2M as of Q1 2026.
  • 22NW LP sold 50,000 Nektar Therapeutics shares in Q1 2026, an estimated $2.85M.
  • Nektar Therapeutics made up 13.86% of 22NW LP's portfolio in Q1 2026, its #2 holding.
  • 22NW LP first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on 22NW LP's 13F filing for Q1 2026, filed 15 May 2026.